References

rsp

Научно-практическая ревматология

Rheumatology Science and Practice

1995-44841995-4492

IMA-PRESS, LLC

10.14412/1995-4484-2019-75-82

rsp-2677

Research Article

НЕПРЕРЫВНОЕ ПОСЛЕДИПЛОМНОЕ ОБРАЗОВАНИЕ ВРАЧЕЙ

CONTINUING POSTGRADUATE EDUCATION PROGRAM FOR PHYSICIANS

Современная фармакотерапия псориатического артрита

Modern pharmacotherapy of psoriatic arthritis

Корсакова

Ю. Л.

Korsakova

Yu. L.

старший научный сотрудник лаборатории диагностики и инновационных методов лечения псориатического артрита, канд. мед. наук;

115522, Москва, Каширское шоссе, 34А

yulkorsakova@bk.ru

Коротаева

Т. В.

Korotaeva

T. V.

заведующая лабораторией диагностики и инновационных методов лечения псориатического артрита, докт. мед. наук;

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

ФГБНУ «Научноисследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation

2019

20032019

5717582

2019

Корсакова Ю.Л., Коротаева Т.В.

Korsakova Y.L., Korotaeva T.V.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://rsp.mediar-press.net/rsp/article/view/2677

В лекции представлены современные принципы лечения псориатического артрита (ПсА) с учетом гетерогенности проявлений этого заболевания и наличия коморбидных состояний, информация об эффективности и переносимости препаратов, которые применяются в Российской Федерации при ПсА.

псориатический артритнестероидные противовоспалительные препаратыглюкокортикоидысинтетические и таргетные синтетические базисные противовоспалительные препаратыгенно-инженерные биологические препараты

psoriatic arthritisnonsteroidal anti-inflammatory drugsglucocorticoidsdisease modifying anti-rheumatic drugsbiologicals

References1

Scarpa R, Altomare G, Marchesoni A, et al. Psoriatic disease: concepts and implications. J Eur Acad Dermatol Venereol. 2010;24:627-30. doi: 10.1111/j.1468-3083.2010.03574.x

Smolen J, Schols M, Braun J, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2017;0:1-15. doi: 10.1136/Ann Rheum Dis-2017-211734

Coates LC, Moverley AR, McParland L, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet. 2015;386(10012):2489-98. doi: 10.1016/S0140-6736(15)00347-5

Gossec L, Smolen, J, Gaujoux-Viala C, et al. European league against rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2012;71:4-12. doi: 10.1136/annrheumdis-2011-200350

Mrowietz U, Domm S. Systemic steroids in the treatment of psoriasis: what is fact, what is fiction? J Eur Acad Dermatol Venereol. 2013;27:1022-5. doi: 10.1111/j.1468-3083.2012.04656.x

Насонов ЕЛ, редактор. Российские клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа; 2018. 464 с. [Nasonov EL, editor. Rossiiskie klinicheskie rekomendatsii. Revmatologiya [Russian clinical guidelines. Rheumatology]. Moscow: GEOTAR-Media; 2018. 464 p. (In Russ.)].

Ceponis A, Kavanaugh A. Use of methotrexate in patients with psoriatic arthritis. Clin Exp Rheumatol. 2010;28:S132-7.

Clegg D, Reda D, Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a department of veteran's affairs cooperative study. Arthritis Rheum. 1999;42:2325-9. doi: 10.1002/1529-0131(199911)42:11<2325::AIDANR10>3.0.CO;2-C

Rahman P, Gladman DD, Cook RJ, et al. The use of sulfasalazine in psoriatic arthritis: a clinical experience. J Rheumatol. 1998;25:1957-61.

Nash P, Thaci D, Behrens F, et al. Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study. Dermatology. 2006;212:238-49. doi: 10.1159/000091251

Sakellariou G, Sayegh F, Anastasilakis A, et al. Leflunomide addition in patients with articular manifestations of psoriatic arthritis resistant to methotrexate. Rheumatol Int. 2013;33:2917-20. doi: 10.1007/s00296-012-2534-x

Behrens F, Finkenwirth C, Pavelka K, et al. Leflunomide in psoriatic arthritis: results from a large European prospective observational study. Arthritis Care Res (Hoboken). 2013;65:464-70. doi: 10.1002/acr.21848

Curtis J, Beukelman T, Onofrei A, et al. Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide. Ann Rheum Dis. 2010;69:43-7. doi: 10.1136/ard.2008.101378

Fraser A, van Kuijk A, Westhovens R, et al. A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis. 2005;64:859-64. doi: 10.1136/ard.2004.024463

Karanikolas G, Koukli E, Katsalira A, et al. Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: results from a prospective 12-month nonrandomized unblinded clinical trial. J Rheumatol. 2011;38:2466-74. doi: 10.3899/jrheum.110242

Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83:1583-90. doi: 10.1016/j.bcp.2012.01.001

Корсакова ЮЛ, Денисов ЛН. Эффективность и безопасность нового препарата для лечения псориаза и псориатического артрита – апремиласта. Научно-практическая ревматология. 2016;54(5):572-7 [Korsakova YuL, Denisov LN. The efficacy and safety of the new drug apremilast for the treatment of psoriasis and psoriatic arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(5):572-7 (In Russ.)]. doi: 10.14412/1995-4484-2016-572-577

Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73:1020-6. doi: 10.1136/annrheumdis-2013-205056

Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Long-term (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis. J Rheumatol. 2015;42:479-88. doi: 10.3899/jrheum.140647

Mease PJ, Adebajo AO, Gladman DD. Long-term (104-week) safety profile of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: results from a phase 3, randomized, controlled trial and open-label extension [abstract]. Arthritis Rheum. 2014;66 Suppl 10:1564.

Cutolo M, Myerson GR, Fleischmann RM, et al. A phase III, randomized, controlled trial of apremilast in patients with psoriatic arthritis: results of the PALACE 2 trial. J Rheumatol. 2016;43:1724-34. doi: 10.3899/jrheum.151376

Edwards CJ, Blanco FJ, Crowley J, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Ann Rheum Dis. 2016;75:1065-73. doi: 10.1136/annrheumdis-2015-207963

Wells A, Edwards C, Adebajo AO. Long-term (104-week) safety and efficacy of monotherapy with apremilast in DMARD-naХve patients with psoriatic arthritis: a phase 3, randomized, controlled trial and open-label extension (PALACE 4) [abstract]. Arthritis Rheum. 2014;66 Suppl. 10:L22.

Mease P, Hall S, FitzGerald O, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med. 2017;377:1537-50. doi: 10.1056/NEJMoa1615975

Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors. N Engl J Med. 2017;377:1525-36. doi: 10.1056/NEJMoa1615977

Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000;356:385-90. doi: 10.1016/S0140-6736(00)02530-7

Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50:2264-72. doi: 10.1002/art.20335

Mease PJ, Kivitz AJ, Burch FX, et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol. 2006;33:712-21.

Sterry W, Ortonne JP, Kirkham B, et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ. 2010;340:c147. doi: 10.1136/bmj.c147

Antoni CE, Kavanaugh A, van der Heijde D, et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol. 2008;35:869-76.

Kavanaugh A, Krueger GG, Beutler A, et al. Infliximab maintains a high degreeof clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis. 2007;66:498-505. doi: 10.1136/ard.2006.058339

Baranauskaite A, Raffayova H, Kungurov NV, et al. Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. Ann Rheum Dis. 2012;71:541-8. doi: 10.1136/ard.2011.152223

Mease PJ, Ory P, Sharp JT, et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis. 2009;68:702-9. doi: 10.1136/ard.2008.092767

Genovese MC, Mease PJ, Thomson GT, et al. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying anti-rheumatic drug therapy. J Rheumatol. 2007;34:1040-50.

Kavanaugh A, McInnes IB, Mease PJ, et al. Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a longterm extension of the randomised, placebo-controlled GOREVEAL study. Ann Rheum Dis. 2013;72:1777-85. doi: 10.1136/annrheumdis-2012-202035

Kavanaugh A, McInnes IB, Mease P, et al. Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study). Ann Rheum Dis. 2014;73:1689-94. doi: 10.1136/annrheumdis-2013-204902

Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis. 2014;73:48-55. doi: 10.1136/annrheumdis-2013-203696

Van der Heijde D, Fleischmann R, Wollenhaupt J, et al. Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol. Ann Rheum Dis. 2014;73:233-7. doi: 10.1136/annrheumdis-2013-203697

Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009;373:633-40. doi: 10.1016/S0140-6736(09)60140-9

McInnes IB, Kavanaugh A, Gottlieb AB, et al. on behalf of the PSUMMIT I Study Group: Efficacy and safety of Ustekinumab in patients with active psoriatic arthritis: 1-year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT I trial. Lancet. 2013;382:780-9. doi: 10.1016/S0140-6736(13)60594-2

Kavanaugh A, Ritchlin C, Rahman P, et al. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis. 2014;73:1000-6. doi: 10.1136/annrheumdis-2013-204741

Kavanaugh A, Puig L, Gottlieb AB, et al. Maintenance of clinical efficacy and radiographic benefit through two years of ustekinumab therapy in patients with active psoriatic arthritis: results from a randomized, placebo-controlled phase III trial. Arthritis Care Res. 2015;67:1739-49. doi: 10.1002/acr.22645

Ritchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional nonbiological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, doubleblind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014;73:990-9. doi: 10.1136/annrheumdis-2013-204655

Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373:1329-39. doi: 10.1056/NEJMoa1412679

Van der Heijde D, Landewe RB, Mease PJ, et al. Secukinumab provides significant and sustained inhibition of joint structural damage in a phase III study of active psoriatic arthritis. Arthritis Rheum. 2016;68:1914-21. doi: 10.1002/art.39685

McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebocontrolled, phase 3 trial. Lancet. 2015;386:1137-46. doi: 10.1016/S0140-6736(15)61134-5

Saad AA, Ashcroft DM, Watson KD, et al. Persistence with antitumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther. 2009;11:52. doi: 10.1186/ar2670

Marchesoni A, Olivieri I, Salvarani C, et al. Recommendations for the use of biologics and other novel drugs in the treatment of psoriatic arthritis: 2017 update from the Italian Society of Rheumatology. Clin Exper Rheumatol. 2017;35:991-1010.

Hyrich KL, Verstappen SM. Biologic therapies and pregnancy: the story so far. Rheumatology. 2014;53(8):1377-85. doi: 10.1093/rheumatology/ket409

Sieper J, van der Heijde DM, Landewe R, et al. New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis. 2009;68(6):784-8. doi: 10.1136/ard.2008.101501

Van der Heijde D, Ramiro S, Landewe R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76:978-91. doi: 10.1136/annrheumdis-2016-210770

Lin VW, Ringold S, Devine EB. Comparison of ustekinumab with other biological agents for the treatment of moderate to severe plaque psoriasis: a bayesian network meta-analysis. Arch Dermatol. 2012;148:1403-10. doi: 10.1001/2013.jamadermatol.238

Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis-results of two phase 3 trials. N Engl J Med. 2014;371:326-38. doi: 10.1056/NEJMoa1314258

The authors declare that there are no conflicts of interest present.